Baseline A1C Level Is the Key
In people with higher A1Cs, rapid-acting insulin analogs NovoLog (insulin aspart) and Humalog (insulin lispro) are more effective in achieving optimal blood glucose control when administered with insulin pumps rather than via multiple daily insulin injections (MDII), according to University of Toronto researchers.
“A model derived from these data predicts that in a patient with a baseline A1C of 10%, [rapid-acting insulin in pumps] would reduce the A1C by an additional 0.65% compared with MDII,” write the researchers. On the other hand, there would be no A1C benefit to using rapid-acting insulin in pumps, compared with MDII, if baseline A1Cs were 6.5%.
The researchers conclude that using fast-acting insulin in pumps may be uniquely advantageous in adults with type 1 diabetes and poor blood glucose control.Click Here To View Or Post Comments